Greenhalgh DG (2017) Sepsis in the burn patient: a different problem than sepsis in the general population. Burns Trauma 5:23. https://doi.org/10.1186/s41038-017-0089-5

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Zou B, Liou YC, Huang C (2021) The pathogenesis and diagnosis of sepsis post burn injury. Burns Trauma 9:tkaa047. https://doi.org/10.1093/burnst/tkaa047

Article  PubMed  PubMed Central  Google Scholar 

Stanojcic M, Vinaik R, Jeschke MG (2018) Status and challenges of predicting and diagnosing sepsis in burn patients. Surg Infect 19(2):168–175. https://doi.org/10.1089/sur.2017.288

Article  Google Scholar 

Torres MJM, Peterson JM, Wolf SE (2021) Detection of infection and sepsis in burns. Surg Infect (Larchmt) 22(1):20–27. https://doi.org/10.1089/sur.2020.348

Article  PubMed  Google Scholar 

Nunez Lopez O, Cambiaso-Daniel J, Branski LK, Norbury WB, Herndon DN (2017) Predicting and managing sepsis in burn patients: current perspectives. Ther Clin Risk Manag 13:1107–1117. https://doi.org/10.2147/TCRM.S119938

Article  PubMed  PubMed Central  Google Scholar 

Liao Q, Feng Z, Lin H et al (2023) Carbapenem-resistant gram-negative bacterial infection in intensive care unit patients: Antibiotic resistance analysis and predictive model development. Front Cell Infect Microbiol 13:1109418. https://doi.org/10.3389/fcimb.2023.1109418

Article  PubMed  PubMed Central  Google Scholar 

Doi Y (2019) Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 69(Suppl 7):S565–S575. https://doi.org/10.1093/cid/ciz830

Liu S, Wu Y, Qi S et al (2023) Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial. Crit Care 27(1):232. https://doi.org/10.1186/s13054-023-04522-6

Article  PubMed  PubMed Central  Google Scholar 

Greenhalgh DG, Saffle JR, Holmes JHT et al (2007) American burn association consensus conference to define sepsis and infection in burns. J Burn Care Res 28(6):776–90. https://doi.org/10.1097/BCR.0b013e3181599bc9

Article  PubMed  Google Scholar 

Zhou C, Jin L, Wang Q et al (2021) Bloodstream infections caused by carbapenem-resistant enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist 14:731–742. https://doi.org/10.2147/IDR.S294282

Article  PubMed  PubMed Central  Google Scholar 

Gutierrez-Gutierrez B, Salamanca E, de Cueto M et al (2017) Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 17(7):726–734. https://doi.org/10.1016/S1473-3099(17)30228-1

Article  PubMed  Google Scholar 

Kellum JA, Lameire N, Group KAGW (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17(1):204. https://doi.org/10.1186/cc11454

Article  PubMed  PubMed Central  Google Scholar 

Martin-Loeches I, Leone M, Madách K, Martin C, Einav S (2017) Antibiotic therapy in the critically ill - expert opinion of the Intensive care medicine scientific subcommittee of the european society of anaesthesiology. Eur J Anaesthesiol 34(4):215–220. https://doi.org/10.1097/EJA.0000000000000595

Article  PubMed  Google Scholar 

Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L (2010) Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54(11):4851–4863. https://doi.org/10.1128/AAC.00627-10

Article  PubMed  PubMed Central  Google Scholar 

Liang Q, Huang M, Xu Z (2019) Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis 23(1):60–65. https://doi.org/10.1016/j.bjid.2018.12.004

Article  PubMed  PubMed Central  Google Scholar 

Liang Q, Chen J, Xu Y, Chen Y, Huang M (2022) Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study. Antimicrob Resist Infect Control 11(1):89. https://doi.org/10.1186/s13756-022-01103-0

Article  PubMed  PubMed Central  Google Scholar 

Greenhalgh DG, Hill DM, Burmeister DM et al (2023) Surviving sepsis after burn campaign. Burns 49(7):1487–1524. https://doi.org/10.1016/j.burns.2023.05.003

Article  PubMed  Google Scholar 

Tang T, Li Y, Xu P et al (2023) Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study. Critical Care 27(1):164. https://doi.org/10.1186/s13054-023-04448-z

Article  PubMed  PubMed Central  Google Scholar 

Tsuji BT, Pogue JM, Zavascki AP et al (2019) International consensus guidelines for the optimal use of polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy 39(1):10–39. https://doi.org/10.1002/phar.2209

Article  PubMed  PubMed Central  Google Scholar 

Miglis C, Rhodes NJ, Avedissian SN et al (2018) Population Pharmacokinetics of Polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother 62(3). https://doi.org/10.1128/AAC.01475-17

Wang P, Zhang Q, Feng M, Sun T, Yang J, Zhang X (2021) Population pharmacokinetics of Polymyxin B in obese patients for resistant gram-negative infections. Front Pharmacol 12:754844. https://doi.org/10.3389/fphar.2021.754844

Article  PubMed  PubMed Central  Google Scholar 

Tang T, Li Y, Xu P et al (2023) Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study. Critical Care 27(1):164. https://doi.org/10.1186/s13054-023-04448-z

Article  PubMed  PubMed Central  Google Scholar 

Tan XYD, Wiseman T, Betihavas V (2022) Risk factors for nosocomial infections and/or sepsis in adult burn patients: an integrative review. Intensive Crit Care Nurs 73:103292. https://doi.org/10.1016/j.iccn.2022.103292

Article  PubMed  Google Scholar 

Sun L, Zhang C, Song P et al (2025) Hypertension and 28-day mortality in sepsis patients: an observational and mendelian randomization study. Heart Lung: J Crit Care 70:147–156. https://doi.org/10.1016/j.hrtlng.2024.11.020

Article  Google Scholar 

de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM (2017) SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care 21(1):38. https://doi.org/10.1186/s13054-017-1609-1

Article  PubMed  PubMed Central  Google Scholar 

Calles J, Cohen B, Forme N, Guendil Z, Fermier B, Chassier C et al (2023) Variation of the sofa score and mortality in patients with severe burns: a cohort study. Burns 49(1):34–41. https://doi.org/10.1016/j.burns.2022.09.004

Article  PubMed  Google Scholar 

Rigatto MH, Behle TF, Falci DR et al (2015) Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70(5):1552–1557. https://doi.org/10.1093/jac/dku561

Article  PubMed  Google Scholar 

Jin J, Zhu J, Zhu Z et al (2022) Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study. Ann Transl Med 10(20):1137. https://doi.org/10.21037/atm-22-4959

Article  PubMed  PubMed Central  Google Scholar 

Wu XL, Long WM, Lu Q et al (2022) Polymyxin B-associated nephrotoxicity and its predictors: a retrospective study in carbapenem-resistant gram-negative bacterial infections. Front Pharmacol 13:672543. https://doi.org/10.3389/fphar.2022.672543

Article  PubMed  PubMed Central  Google Scholar 

Dubashynskaya NV, Skorik YA (2020) Polymyxin Delivery Systems: Recent Advances and Challenges. Pharmaceuticals (Basel) 13(5):83. https://doi.org/10.3390/ph13050083

Article  PubMed  Google Scholar